Navigation Links
Adrenaline receptor 'frozen in action' by VIB researchers
Date:1/12/2011

Brussels - Adrenaline, the hormone that prepares our body to fight or flight, acts on a hyperdynamic receptor. This molecule switches so fast between several positions, that it was impossible to image it. Until now. Scientists, including Jan Steyaert of VIB and the Vrije Universiteit Brussel in Belgium, and colleagues from Stanford University in the US, have "frozen the molecule in action" using Xaperones, tiny, stable antibodies developed by the Brussels scientists. The Xaperones bind like a key to a lock, holding the adrenaline receptor in one position -- the on position. After binding the adrenaline receptor to the Xaperone, the researchers could use X-ray crystallography techniques to determine its structure. The results are published in Nature.

Prospects for medicine

The breakthrough is not only a scientific first, the newly developed technique also offers promising prospects for medicine. The adrenaline switch is the target of widely used drugs such as asthma inhibitors and beta blockers. The latter are used worldwide as a medicine for heart disease.

But the applications are not limited to asthma or heart disease. Over 30% of all drugs on sale in pharmacies today switch similar receptors on or off. Through the newly developed technique, these receptors can now be accurately described, which is a necessary first step to determine their action and develop new or better drugs.

Receptors as switches in the body

Adrenaline is a hormone that is released under stress. It is a messenger molecule which causes the heart to beat faster, causes us to sweat suddenly and releases sugar as an immediately usable source of energy. These reactions are the result of the fact that adrenaline binds with a specific switch (known as beta2-adrenergic receptor). This switch is embedded in the membrane surrounding our cells. When adrenaline binds to the receptor, the individual cell knows that the rest of the body is preparing for stress reactions such as fight or flight.

It is impossible to determine the structure of this kind of switches by using conventional methods. They move, oscillate and constantly change position, even when the signalling molecule such as adrenaline is absent. Together with researchers from Stanford University, Jan Steyaert and his colleagues have managed as it were to freeze the adrenaline switch in the "on" position. For this purpose, they used a Xaperone which attaches like a key in a lock to the switch and causes it to stop switching from one position to another. It is in this "frozen" on-position that the structure was determined using X-ray crystallography techniques.

Our body is equipped with hundreds of similar continually moving switches which determine how we react to our environment. The scientific term for these switches is GPCR (G-Protein-coupled receptors). The newly developed technique based on Xaperones can also be widely used in studying other GPCRs and proteins with therapeutic relevance.

Xaperones is a new application of the Nanobody technology developed at VIB-Vrije Universiteit Brussel. The development of therapeutic Nanobodies forms the basis of the biopharmaceutics company Ablynx, a start-up of VIB and Vrije Universiteit Brussel.

Frozen in action

The solution to fix proteins with Xaperones is comparable to the solution which the English scholar Eadweard Muybridge conceived of around 1900 to be able to study fast-moving objects. He was the first to prove, on the basis of a series of still photographs, that a galloping horse sometimes has all its legs off the ground. http://en.wikipedia.org/wiki/Eadweard_Muybridge


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Carnegie Mellon researchers discover mechanism for signaling receptor recycling
2. Discovery of taste receptors in the lungs could help people with asthma breathe easier
3. Amid the murk of gut flora, vitamin D receptor emerges as a key player
4. Connecting the dots: How light receptors get their message across
5. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
6. Receptor variant influences dopamine response to alcohol
7. Gene-based stem cell therapy specifically removes cell receptor that attracts HIV
8. Stress peptide and receptor may have role in diabetes
9. Developmental delay could stem from nicotinic receptor deletion
10. Common herbicides and fibrates block nutrient-sensing receptor found in gut and pancreas
11. Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
(Date:2/24/2017)... 2017  VWR Corporation (NASDAQ: VWR), the leading global independent ... customers, today reported its financial results for the fourth quarter ... 4Q16 record quarterly net sales of ... organic basis. 4Q16 EMEA-APAC segment ... while the Americas net sales increased 2.5%, or down 0.9% ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology: